CA2362930A1 - Inhibiteurs de la pompe a proton nitroses et nitrosyles, compositions et procedes d'utilisation - Google Patents

Inhibiteurs de la pompe a proton nitroses et nitrosyles, compositions et procedes d'utilisation Download PDF

Info

Publication number
CA2362930A1
CA2362930A1 CA002362930A CA2362930A CA2362930A1 CA 2362930 A1 CA2362930 A1 CA 2362930A1 CA 002362930 A CA002362930 A CA 002362930A CA 2362930 A CA2362930 A CA 2362930A CA 2362930 A1 CA2362930 A1 CA 2362930A1
Authority
CA
Canada
Prior art keywords
group
compound
nitric oxide
hydrogen
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002362930A
Other languages
English (en)
Other versions
CA2362930C (fr
Inventor
David S. Garvey
L. Gordon Letts
Sang William Tam
Tiansheng Wang
Stewart K. Richardson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2362930A1 publication Critical patent/CA2362930A1/fr
Application granted granted Critical
Publication of CA2362930C publication Critical patent/CA2362930C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention a pour objet de nouveaux composés nitrosés et/ou nitrosylés inhibiteurs de la pompe à protons, et de nouvelles compositions comportant au moins un composé inhibiteur de la pompe à protons, éventuellement substitué par au moins un groupe NO et/ou NO2, et éventuellement au moins un composé qui donne, transfère ou émet de l'oxyde nitrique, stimule la synthèse endogène de l'oxyde nitrique, élève les niveaux endogènes de facteur de relaxation dérivé de l'endothélium ou constitue un substrat pour la synthase de l'oxyde nitrique, et/ou au moins un médicament anti-inflammatoire non stéroïdien, un antiacide sélectif inhibiteur de COX-2, un réactif contenant du bismuth, un composé antibactérien dégradable à l'acide et des mélanges de ceux-ci. La présente invention a également pour objet des méthodes pour traiter et/ou prévenir les troubles gastro-intestinaux; faciliter la cicatrisation des ulcères; réduire la récurrence des ulcères; améliorer les propriétés de protection gastrique, les propriétés anti-helicobacter pylori ou les propriétés antiacides des inhibiteurs de la pompe à protons; diminuer ou supprimer la toxicité gastro-intestinale associée à l'utilisation de composés anti-inflammatoires non stéroïdiens; traiter les infections à helicobacter pylori et les infections virales. Les composés et/ou les compositions de la présente invention peuvent également se présenter sous la forme d'une trousse pharmaceutique.
CA2362930A 1999-02-26 2000-02-25 Inhibiteurs de la pompe a proton nitroses et nitrosyles, compositions et procedes d'utilisation Expired - Fee Related CA2362930C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12211199P 1999-02-26 1999-02-26
US60/122,111 1999-02-26
PCT/US2000/002524 WO2000050037A1 (fr) 1999-02-26 2000-02-25 Inhibiteurs de la pompe a proton nitroses et nitrosyles, compositions et procedes d'utilisation

Publications (2)

Publication Number Publication Date
CA2362930A1 true CA2362930A1 (fr) 2000-08-31
CA2362930C CA2362930C (fr) 2010-10-05

Family

ID=22400684

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2362930A Expired - Fee Related CA2362930C (fr) 1999-02-26 2000-02-25 Inhibiteurs de la pompe a proton nitroses et nitrosyles, compositions et procedes d'utilisation

Country Status (5)

Country Link
EP (1) EP1154771A4 (fr)
JP (1) JP2002537336A (fr)
AU (2) AU781133B2 (fr)
CA (1) CA2362930C (fr)
WO (1) WO2000050037A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
WO2003043614A2 (fr) * 2001-11-19 2003-05-30 Altana Pharma Ag Agents utiles pour le traitement des troubles des voies aeriennes
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
EP1487447A1 (fr) * 2002-03-14 2004-12-22 ALTANA Pharma AG Utilisation d'inhibiteurs de la pompe a protons pour traiter des troubles des voies respiratoires
WO2003082854A1 (fr) * 2002-03-29 2003-10-09 Zeria Pharmaceutical Co., Ltd. Derives 1-n-aminobenzimidazole
EP1497268A4 (fr) * 2002-04-05 2006-01-18 Nitromed Inc Donneurs de monoxyde d'azote, compositions et procedes d'utilisation, applications correspondantes
US7211590B2 (en) 2002-08-01 2007-05-01 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
EP1718303A4 (fr) * 2004-02-10 2010-09-01 Santarus Inc Combinaison d'un inhibiteur de la pompe a protons, d'un tampon et d'un medicament anti-inflammatoire non steroidien
TW200606163A (en) 2004-04-22 2006-02-16 Eisai Co Ltd Imidazopyridine compound
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
US9040564B2 (en) 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
US20090018091A1 (en) 2005-08-02 2009-01-15 Nitromed, Inc. Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use
JP5075254B2 (ja) 2011-01-07 2012-11-21 スノーデン株式会社 胃酸及びガストリンの産生を抑制する乳酸菌
WO2021170093A1 (fr) * 2020-02-26 2021-09-02 上海科技大学 Application de disulfirame dans la résistance contre le coronavirus

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117268A (ja) * 1991-10-22 1993-05-14 Yoshitomi Pharmaceut Ind Ltd ピリジン化合物
IL105155A (en) * 1992-04-24 1999-05-09 Astra Ab Synergistic combination of an inhibitor of gastric acid secretion with an acid-breaking antibiotic
SG49853A1 (en) * 1993-08-16 2001-07-24 Novartis Ag Novel macrolides and the use thereof
SK283268B6 (sk) * 1994-06-10 2003-04-01 Altana Pharma Ag Tiopyridíny, spôsob ich výroby a ich použitie
NZ288609A (en) * 1994-06-10 1998-12-23 Byk Gulden Lomberg Chem Fab Substituted (4-thiopyridinyl) methylthio-benzimidazole (or 1h-imidazo-[2,3-b]-pyridine) and medicaments
DE4420523A1 (de) * 1994-06-13 1995-12-14 Cassella Ag Verwendung von NO-freisetzenden Verbindungen zur Behandlung und Vorbeugung von systemischen Entzündungssyndromen
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
CA2271381A1 (fr) * 1996-11-22 1998-05-28 Owen Rickford Carryl Compositions et methodes pour traiter des troubles gastro-intestinaux
EA001734B1 (ru) * 1996-12-20 2001-08-27 Бык Гульден Ломберг Хемише Фабрик Гмбх Имидазопиридазины
US6051570A (en) * 1997-05-30 2000-04-18 Dr. Reddy's Research Foundation Benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO2000050037A1 (fr) 2000-08-31
AU781133B2 (en) 2005-05-05
AU2005202553A1 (en) 2005-07-07
JP2002537336A (ja) 2002-11-05
AU3219600A (en) 2000-09-14
EP1154771A1 (fr) 2001-11-21
CA2362930C (fr) 2010-10-05
EP1154771A4 (fr) 2005-04-20

Similar Documents

Publication Publication Date Title
CA2362930A1 (fr) Inhibiteurs de la pompe a proton nitroses et nitrosyles, compositions et procedes d'utilisation
JP2005539013A5 (fr)
AU2002230618B2 (en) Heterocyclic ether substituted imidazoquinolines
AU2006295645B2 (en) 2-heteroaryl-substituted indole derivative
US6664260B2 (en) Heterocyclic ether substituted imidazoquinolines
JP4634144B2 (ja) ニトロソ化プロトンポンプ阻害剤、組成物および使用方法
CA2631880A1 (fr) Benzimidazoles substitues par des chromanes et leur utilisation en tant qu'inhibiteurs de la pompe a protons
KR20010103566A (ko) 양성자 펌프 억제제의 프로드러그
KR20120028869A (ko) β-세크레타제 억제제로서 치환된 이미다조［1,2-Ａ］피리딘 유도체, 약제학적 조성물, 및 사용 방법
JP2002537336A5 (fr)
KR20080035661A (ko) 감염 방지제로서 사용되는8-메톡시-9ｈ-이소티아졸로［5,4-ｂ］퀴놀린-3,4-디온 및관련 화합물
AU2016252686A1 (en) 6-membered heterocyclic derivative and pharmaceutical composition comprising same
KR20060051002A (ko) 피롤로[3,2-ｃ]피리딘 유도체 및 그의 제조방법
US5859030A (en) Substituted arylalkylthioalkylthiopyridines for use in the control of helicobacter bacteria
KR20060017865A (ko) 환상 3급 아민 화합물
CA2152817C (fr) Nouveaux derives de l'acide pyridonecarboxylique
BRPI0916475A2 (pt) imidazo[1,2-a]piridina substituída, de fórmula i ou um sal farmaceuticamente aceitável da mesma, processo para a preparação da imidazo[1,2-a]piridina substituída, composição farmacêutica, e, uso da imidazo[1,2-a]piridina substituída
CN102827186A (zh) 一类吡啶并五元杂环衍生物及其制备方法和用途
CA2974697A1 (fr) Derives de pyrimidine-2,4-(1h,3h)-dione, compositions pharmaceutiques connexes et utilisation comme inhibiteurs des transporteurs de monocarboxylate
TW201742867A (zh) 新穎5H-吡咯并[2, 3-d]嘧啶-6(7H)-酮衍生物
BRPI0709595A2 (pt) inibidores de nf-kapab heterocìclicos
CA3140017A1 (fr) Derives d'uree polyaromatiques et leur utilisation dans le traitement de maladies musculaires
WO2007124545A1 (fr) Inhibiteurs d'intégrase-2
UA57056C2 (uk) Імідазопіридазини та лікарський засіб
RU2006141255A (ru) Соединение имидазопиридина

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed